Fig. 2: ELAVL3 is essential for the development and maintenance of neuroendocrine prostate cancer. | Nature Communications

Fig. 2: ELAVL3 is essential for the development and maintenance of neuroendocrine prostate cancer.

From: The ELAVL3/MYCN positive feedback loop provides a therapeutic target for neuroendocrine prostate cancer

Fig. 2

a Volcano plots showing enrichment of RNA most significantly bound to ELAVL3-V5 in PC3 (left) and DU145 (right). Fold change >2; adjusted P-value < 0.05, calculated by wald test. Venn diagram showing overlap between putative ELAVL3 mRNA targets from PC3 and DU145. b Hallmark and KEGG pathway enrichment analysis of samples with transcripts simultaneously bound to ELAVL3-V5 from PC3/ELAVL3-V5 and DU145/ELAVL3-V5 using Metascape25. c QPCR showing relative mRNA expression of indicated genes (left) and Western blot showing indicated protein expression (right) in LNCaP/Ctrl and LNCaP/ELAVL3. d QPCR showing relative mRNA expression of indicated genes in NCI-H660/shCtrl and NCI-H660/shELAVL3. e QPCR showing relative mRNA expression of indicated genes (left) and Western blot showing indicated protein expression (right) in LASCPC-01/shCtrl and LASCPC-01/shELAVL3. f QPCR showing relative mRNA expression of indicated genes in shELAVL3 versus shCtrl of LNCaP/AR/shTP53/shRB1 (LAPR). g KEGG pathway enrichment analysis of differentially expressed genes from shELAVL3 versus shCtrl in LAPR. h Photograph showing LASCPC-01 xenografts in nude mice with shCtrl and two independent shRNAs targeting ELAVL3 (left). Tumor volume was measured once a week at indicated time points (middle, n = 6 per group). Tumor weight was measured when sacrificed (right, n = 6 per group). i Representative H&E and immunohistochemistry staining (upper; scale bar, 50 μm) and quantification (bottom; n = 9) of indicated staining in LASCPC-01 xenografts. j Cell viability of LAPR/shCtrl and LAPR/shELAVL3 treated with 10 μM Enzalutamide at indicated time points (n = 3 biologically independent experiments). k Cell viability of LNCaP/Ctrl and LNCaP/ELAVL3 treated with 10 μM Enzalutamide at indicated time points (n = 3 biologically independent experiments). l Cell viability of LNCaP/Ctrl and LNCaP/ELAVL3 treated with increasing concentration of Enzalutamide for 48 h (n = 3 biologically independent experiments). Data presented as mean ± s.e.m. (c–f, h–l). Statistical significance was determined by one-way ANOVA with Dunnett’s multiple comparisons (e), or two-tailed unpaired Student’s t-test (c, d, f, h–l). Western blot experiments were repeated three times independently, with similar results (c, e). QPCR experiments were conducted n = 3 biologically independent experiments. Source data are provided as a Source Data file.

Back to article page